Ignite Creation Date:
2024-10-25 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06506838
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-12
Brief Title:
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Prospective Open-Label Single-Arm Clinical Study of Anlotinib Combined With Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Detailed Description:
This is a a prospective open-Label and single-arm clinical study This study aims to evaluate the efficacy and safety of using anlotinib in combination with doxorubicin monotherapy and radiotherapy as a neoadjuvant treatment for soft tissue sarcoma For patients with the soft tissue sarcoma the standard doxorubicin monotherapy regimen involves administering 375 mgm² intravenously on days 1-2 of each 3-week cycle The treatment includes 3 cycles of neoadjuvant chemotherapy pre-surgery and 3 cycles of adjuvant chemotherapy post-surgery totaling 6 cycles Anlotinib ALC is administered at 12mgd QDday114 21dcycle Neoadjuvant radiotherapy is conducted before surgery starting after the second chemotherapy cycle using stereotactic body radiation therapy SBRT with a dose of 410 Gy Radical resection surgery is performed in the ninth week after the third chemotherapy cycle
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None